Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients

Bei-Ge Jiang; Neng Wang; Jian Huang; Yuan Yang; Liang-Liang Sun; Ze-Ya Pan; Wei-Ping Zhou

doi:10.18632/oncotarget.16157

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients

Bei-Ge Jiang, Neng Wang, Jian Huang, Yuan Yang, Liang-Liang Sun, Ze-Ya Pan and Wei-Ping Zhou _

PDF | HTML | How to cite

Oncotarget. 2017; 8:28621-28627. https://doi.org/10.18632/oncotarget.16157

Metrics: PDF 1447 views | HTML 2338 views | ?

Abstract

Bei-Ge Jiang1,*, Neng Wang1,*, Jian Huang1,*, Yuan Yang1, Liang-Liang Sun2, Ze-Ya Pan1, Wei-Ping Zhou1

1Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P.R. China

2Department of Endocrinology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, P.R. China

*These authors contribute equally to this work

Correspondence to:

Wei-Ping Zhou, email: [email protected]

Ze-Ya Pan, email: [email protected]

Liang-Liang Sun, email: [email protected]

Keywords: suppressor of cytokine signaling, transarterial chemoembolization, methylation, prognosis

Received: September 30, 2016 Accepted: January 24, 2017 Published: March 13, 2017

ABSTRACT

Background: Suppressor of cytokine signaling (SOCS) 1 and 3 methylation have been associated with clinical features and outcomes of cancer patients. However, their roles in determining the treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) remain unknown.

Results: We found that presence of SOCS3 methylation is significantly associated with the major clinical features of HCC patients, including tumor stage, lymph node and vascular invasion. Of note, we observed that the presence of SOCS3 methylation is closely related to TACE response. In prognosis analyses, HCC patients with SOCS3 methylation presence have a poorer prognosis indicated by lower 3-, and 5-year survival rates and shorter mean survival period, than those without. Multivariate COX analysis confirms the prognostic role of the presence of SOCS3 methylation in HCC patients receiving TACE treatment.

Materials and Methods: A total of 246 HCC patients receiving TACE were enrolled in this study. Tumor samples was obtained from echo-guided fine needle aspiration and genomic DNA from tumor samples was purified. SOCS1 and SOCS3 methylation status were detected using methylation-specific polymerase chain reaction. The treatment responses to TACE of patients were evaluated after procedure and all patients were followed for prognosis analysis.

Conclusions: This finding suggests that the presence of SOCS3 methylation is a marker to predict treatment response and prognosis in HCC patients receiving TACE therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16157

Publication Alerts

Research Papers:

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients

Abstract